{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018243","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.484218+00:00","generated_at":"2026-06-23T12:40:56.429299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April","bullets":["No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.","Net loss widened to $23.0M from $16.1M; cash burn reflects higher operating expenses.","KVD824 Phase 2 KOMPLETE trial passed 50% enrollment; top-line data expected mid-2023.","Open-label extension (KONFIDENT-S) initiated for sebetralstat; Phase 3 KONFIDENT data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018243","json":"https://secwatch.observer/filing/0000950170-22-018243.json","markdown":"https://secwatch.observer/filing/0000950170-22-018243.md","text":"https://secwatch.observer/filing/0000950170-22-018243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/0000950170-22-018243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/kalv-20220908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:40:56.429299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}